{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-014914","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.699482+00:00","generated_at":"2026-06-16T03:10:39.022386+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aquestive Q1 net income $8.1M vs loss; raises FY revenue guidance to $42-46M","bullets":["Net income $8.1M ($0.11 diluted EPS) vs net loss $13.2M ($0.32 loss) in Q1 2022.","Total revenue $11.1M, down from $12.3M YoY; excluding prior Sympazan sales, revenue +10%.","Non-GAAP adjusted EBITDA loss improved to $3.9M from $8.1M.","Raises FY2023 guidance: revenue $42-46M (prev. $37-41M); adj EBITDA loss $24-28M (prev. $31-36M).","Two shareholder lawsuits dismissed with prejudice in April 2023; brand name Anaphylm conditionally accepted by FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-014914","json":"https://secwatch.observer/filing/0001628280-23-014914.json","markdown":"https://secwatch.observer/filing/0001628280-23-014914.md","text":"https://secwatch.observer/filing/0001628280-23-014914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/0001628280-23-014914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/aqst-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:10:39.022386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcc4cc85821e38f27a035a87bf87b8bbd1f5c056","claim":"Aquestive Therapeutics, Inc. updated its first quarter ended March 31, 2023 guidance (raised).","evidence_excerpt":"On May 2, 2023, Aquestive Therapeutics, Inc. (the \"Company\") issued a press release announcing its reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments in its business.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/0001628280-23-014914-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}